XRAY is a reliable source of cancer-related news and information.
XRAY Quarterly Digest
FORCE developed our XRAY-Behind the Headlines program to help people separate relevant cancer news from hype by providing honest evaluations of cancer research reported in the media. 
 
The XRAY Quarterly Digest provides a compilation of XRAY reviews published over the last three months.
Spanish language portal
XRAY reviews and webinars are now available in Spanish!

We have a new portal on the FORCE website with resources in Spanish. These include select XRAY reviews translated into Spanish and on-demand webinars. New XRAY reviews will be translated into Spanish and added on an ongoing basis.  Please check out these resources and let others know they are available.


Visit the Spanish language portal

 
Circulating tumor DNA
Breast cancer patients voice experience with hormone therapy

Many breast cancer patients do not begin or complete hormone therapy. Patients point to a need for tools to manage side effects and improve provider communication. Hear about their experiences in our XRAY review.


Read the review

 
Imagining for prostate cancer
New imaging drug detects prostate cancer spread

The FDA has approved a new imaging method for prostate cancer using the first PSMA-targeted imaging drug. This tracer targets prostate cells to identify new or recurrent metastatic prostate cancer. Read more in our XRAY review.


Read the review

 
Delayed ovary removal
Women support delayed removal of ovaries

Can women at high risk of ovarian cancer wait to remove their ovaries? High-risk women found removal of fallopian tubes with delayed ovary removal acceptable. Read more in our XRAY review.


Read the review

 
Keytruda
Keytruda approved for advanced colorectal cancer  
 
Keytruda (pembrolizumab) was more successful than chemotherapy in delaying advanced colorectal cancer progression. Read more about the KEYNOTE-177 study leading to FDA approval in our XRAY review.


Read the review

 
Trodelvy for triple-negative breast cancer
Metastatic triple-negative breast cancer outcomes are improved by Trodelvy 
 
The smart drug sacituzumab govitecan-hizy (Trodelvy) improved survival of people with previously treated metastatic triple-negative breast cancer in the ASCENT trial. This supports use of Trodelvy as a standard therapy for pretreated metastatic triple-negative breast cancer.


Read the review

 
Bee venom for treating breast cancer
The buzz about honeybee venom for treating breast cancer

Melittin, an ingredient in honeybee venom, can kill HER2-positive and triple-negative breast cancer cells in the lab. Learn more about this promising, early drug in our XRAY review.


Read the review

 
Inherited mutations in Spanish families with pancreatic cancer
Inherited mutations in Spanish families with pancreatic cancer

What mutations are linked to inherited pancreatic cancer? In a Spanish study, most are in genes associated with other cancers. This link indicates the need for genetic testing for people with a family history of pancreatic cancer. 


Read the review

 
BRCA status awareness brings better outcomes
Knowing about an inherited BRCA mutation improves outcomes

Women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. Read more in our XRAY review. 


Read the review

 
Breast implant related illness and cancer
Rare but harmful events linked to breast implants

The FDA has updated reported cases of breast implant-associated cancer and breast implant illness. Read our XRAY review for more details and new resources for reporting information about quality of life and satisfaction with breast implants. 


Read the review

 
                   .  
 
 
 
Facing Our Risk of Cancer Empowered, 16057 Tampa Palms Blvd. W #373, Tampa, FL 33647

FORCE®, FORCE FACING OUR RISK OF CANCER EMPOWERED®, JOINING FORCES AGAINST HEREDITARY CANCER®, PREVIVOR® and the FORCE Ribbon Design are registered trademarks of FORCE-Facing Our Risk of Cancer Empowered, Inc. in the United States. Unauthorized reproduction or use of FORCE’s trademarks is prohibited.